Patent application number | Description | Published |
20080274966 | Biglycan and related therapeutics and methods of use - The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders. | 11-06-2008 |
20100130405 | BIGLYCAN AND RELATED THERAPEUTICS AND METHODS OF USE - The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders. | 05-27-2010 |
20110053854 | TREATMENT OF MUSCULAR DYSTROPHIES AND RELATED DISORDERS - The invention provides, among other aspects, compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; diseases or conditions associated with an abnormal level or activity of collagen VI; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); and disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. | 03-03-2011 |
20110183910 | BIGLYCAN AND RELATED THERAPEUTICS AND METHODS OF USE - The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders. | 07-28-2011 |
Patent application number | Description | Published |
20120004178 | BIGLYCAN MUTANTS AND RELATED THERAPEUTICS AND METHODS OF USE - The present disclosure provides compositions and methods for treating diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders. | 01-05-2012 |
20140038906 | THERAPEUTIC AND DIAGNOSTIC METHODS INVOLVING BIGLYCAN AND UTROPHIN - The present disclosure provides methods for predicting a patient's response to biglycan therapy for diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of such diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders. This application also provides combination therapeutics, such as a biglycan therapeutic and a utrophin therapeutic. | 02-06-2014 |
Patent application number | Description | Published |
20100157313 | Test Method for Surface Figure of Large Convex Mirrors - A method of testing a convex mirror surface figure in which an optical quality substrate material is used having a convex front surface and a rear surface polished to a precise optical figure to create a lens. The lens is then tested by a standard interferometric or wavefront lens-testing method and the convex surface coated once a desired curvature is obtained. Null testing may be attained by passing a collimated interferometer beam through a focusing lens shaped to counter the predicted spherical aberration introduced by a perfect convex mirror/lens. | 06-24-2010 |
20100157314 | Test Method For Surface Figure of Large Convex Mirrors - A method of testing a convex mirror surface figure in which an optical quality substrate material is used having a convex front surface and a rear surface polished to a precise optical figure to create a lens. The lens is then tested by a standard interferometric or wavefront lens-testing method and the convex surface coated once a desired curvature is obtained. Null testing may be attained by passing a collimated interferometer beam through a focusing lens shaped to counter the predicted spherical aberration introduced by a perfect convex mirror/lens. A nominal rear surface figure of the mirror/lens may be used if a precisely figured test window is contacted with the rear surface using a refractive index-matching substance with an index of refraction closely matching the index of refraction of the test optic. | 06-24-2010 |
20100277723 | Systems and Methods For Remote Unmanned Raman Spectroscopy - A Raman spectroscopy sensor integrated with an unmanned ground vehicle (UGV) includes a UGV having a robot arm and a camera mounted on the robot arm. A laser and telescope associated with a Raman sensor are mounted on the robot arm in such a way as to point in substantially the same direction in which the camera is pointed. A Raman spectral data acquisition and control module is mounted on the UGV and is configured to receive Raman spectral data from the telescope. A remote base station having a display and a data processing and analysis module is configured to receive data from the data acquisition and control module and to display for an operator images from the camera and information related to the Raman sensor. An autofocus system is preferably employed to automatically control telescope focus and thereby enable the Raman sensor to operate over a wide range, e.g., 0.5 m to 10 m. | 11-04-2010 |
20110063611 | QUANTUM EFFICIENCY ENHANCEMENT DEVICE FOR ARRAY DETECTORS - Systems and methods for increasing the quantum efficiency of a photocathode used in an intensified an intensified array detector with a photocathode, such as a charge-coupled device (ICCD) are presented. A quantum efficiency enhancement device is disposed in front of an ICCD and is configured to enable or facilitate an increase in the angle of incidence of incoming rays incident on the photocathode. The ICCD itself may be tilted to achieve an increased angle of incidence, and such tilting is preferably only in a direction in which pixel columns of the ICCD extend such that a plane of incidence of incoming light to the ICCD is perpendicular to a direction of wavelength dispersion. The quantum efficiency enhancement device may include re-imaging optics, an optical tilt compensator and optical coupler. | 03-17-2011 |
20120259447 | Surface Figure Test Method For Large Convex Optical Surfaces - A method of testing figure quality of a convex mirror in which an optical quality substrate material is used. The substrate has a front convex surface that has to be polished and figured to high accuracy, typically λ/10 (HeNe), and a rear concave surface which only needs to be polished and figured to moderate surface figure accuracy, typically about 1-λ (HeNe). Three separate interferometric null tests are then carried out to produce three independent sets of optical path difference (OPD) data. Null lenses, or nulling computer generated holograms (CGHs), are designed and used as needed in each test setup so that spherical aberration is corrected. All three separate interferometric tests are either ideal null tests, or near null tests. From the three sets of OPD data, surface figure errors on the rear and front surfaces of the test optic, h | 10-11-2012 |